Table 1

Changes in the IMT in the three groups

Group 1Group 2Group 3p Value
Mean IMT (mm)
 Baseline0.70 (0.63–0.74)0.71 (0.60–0.73)0.79 (0.74–0.83)0.010*
 3 Months0.68 (0.64–0.73)0.67 (0.62–0.70)
 2 Years0.63 (0.59–0.75)0.67 (0.62–0.74)0.82 (0.71–0.86)
Maximum IMT (mm)
 Baseline0.81 (0.70–0.90)0.78 (0.71–0.84)0.90 (0.81–1.15)0.013*
 3 Months0.80 (0.70–0.89) 0.74 (0.70–0.79)
 2 Years0.75 (0.65–0.85) 0.78 (0.70–0.82)0.87 (0.82–1.12)
Annualised rate of change, mean (95% CI) (mm/year)
 Mean IMT−0.0137 (−0.0381 to 0.0106)−0.0069 (−0.0294 to 0.0156)0.0129 (0.0001 to 0.0257)0.058
 Maximum IMT−0.0223 (−0.0392 to −0.0054)−0.0167 (−0.0487 to 0.0153)−0.0077 (−0.0317 to 0.0163)0.713
  • Data are expressed as median (interquartile range). Group 1, psoriatic arthritis (PsA) patients continued on tumour necrosis factor (TNF) blockers; Group 2, PsA patients discontinued TNF blockers after 3 months; Group 3, TNF blocker-naive PsA patients.

  • * Kruskal–Wallis test comparing differences at baseline between the three groups.

  • p<0.05 using Wilcoxon signed ranks test comparing changes with baseline.

  • Analysis of variance test comparing differences between the three groups.

  • IMT, intima-media thickness.